This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Good morning, ladies and gentlemen. Welcome to the Biopath Holdings first quarter 2021 earnings conference call. At this time, all participants are in a listen-only mode. Following the former remarks, we will open the call up for your questions. I would now like to turn the call over to Will O'Connor of Stern Investor Relations. Please proceed.
spk01: Thank you, Operator. Welcome to the Biopath Holdings conference call and webcast to review the company's first quarter 2021 financial results. and to provide an update on recent pipeline and corporate developments. Earlier, we issued a press release which outlines the topics that we plan to discuss on today's call. The release is available at biopathholdings.com. With me today from Biopath are President and CEO Peter Nielsen and Senior Vice President of Finance, Accounting, and Administration Anthony Price. Before we begin, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we urge you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Biopath CEO, Peter Nielsen. Thanks, Will.
spk07: Good morning, everyone, and thank you for joining us. 2021 is off to a terrific start. marked by substantial progress across our portfolio of targeted nucleic cancer drugs. We are excited by the advances we've made, but are even more excited by what is to come for Biopath. Let me now turn to discuss these advances and opportunities in greater detail. I'll begin with our lead product candidate, Prexager Burrison, where we continue to make solid progress. In April, we were delighted to publish an analysis highlighting the potential of Prexagibiricin within the antisense oligonucleotide drug delivery landscape in the peer-reviewed journal Biomedicines. In addition, stage two of our phase two clinical trial of Prexagibiricin for the treatment of acute myeloid leukemia, or AML, in combination with frontline therapy, Decidamin and Venetoclax continues. As we have previously reported, Phase II clinical development of Prexagibiricin and AML commenced with Stage I of our Phase II clinical trial, which was open-label and treated de novo AML patients with a combination of Prexagibiricin and low-dose Cytaribin, or LDAC. The combination of Prexagibiricin and LDAC was shown to be safe and more efficacious to treat this class of patients than with LDAC alone. As many of you know, there has been an evolving landscape for standard of care in AML. Despite these new therapies, there are still patients who are refractory or resistant, and those are the patients we aim to help. As standard of care evolved, we adapted our trial design to reflect these changes. The amended stage two of this phase two trial in AML is an open-label Phase II two-stage multicenter study of Prexager-Burison in combination with Decidamin and Venetoclax in two cohorts of patients with previously untreated AML and relapsed-resistant AML. A third cohort includes treating relapsed-resistant AML patients who are Venetoclax-resistant or intolerant with the two-drug combination of Prexager-Burison and Decidamin. The full trial design plans have approximately 54 evaluable patients for the cohort-treating relapsed refractory AML patient with the triple-combination treatment of Prexagibiricin, Decitamin, and Venetoclax, and the cohort-treating AML patients who are Venetoclax-resistant or intolerant with the two-dose combination of Prexagibiricin and Decitamin. with a review of both cohorts performed after 19 evaluable patients. The full trial design plans have approximately 98 evaluable patients for the cohort treating untreated AML patients, with a triple combination treatment of Prexagibiricin, Decidivin, and Venetoclax, with a preliminary review of the cohort performed after 19 evaluable patients, and a formal interim analysis after 38 available patients. The higher number of patients in the folder trial design for the untreated AML patient cohort is due to the higher baseline response of the frontline therapy with previously untreated AML patients. The primary endpoint for this study will be the number of patients who achieve complete remission which includes complete remission with incomplete hematologic recovery and complete remission with partial hematologic recovery. An interim analysis will be formed on each cohort to assess the safety and efficacy of the treatment. In April, we were excited to announce the successful completion of a study run-in of stage two of the phase two, which had a clean side effect profile and lack of toxicity. We are also very encouraged by the efficacy signal shown in this data set, with five of the six evaluable relapse, refractory, and newly diagnosed AML patients demonstrating clinical activity. We look forward to advancing this study, as we believe its unique design provides us with several definable registration pathways. As I mentioned on our last call, The United States Patent and Trademark Office issued a third patent in our family of platform intellectual property that offers expanded defense of our de-enabilized platform technology. In addition, we were pleased to receive the issuance of a patent related to Prexager Burrison in combination with either cytodyne analogs such as dacitamin or the BCR-abled tyrosine kinase inhibitors, dasatinib and nilotinib. This addition further strengthens our intellectual property portfolio and completes our already granted patents. These new patents protect the unique therapy combination and supports our ongoing investment in this program to bring a new treatment option to patients with AML who have limited treatment options. As I have said before, we will continue our efforts to build a fortress of protection around our technology as it safeguards our platform technology and target-specific technology and is a deterrent to would-be competitors and creates value around our core competencies. Next, I'd like to turn to our planned phase one clinical trial in Prexager-Burison-A in patients with advanced solid tumors, including ovarian, uterine, pancreatic, and hormone refractory breast cancer. Prexigerboricin-A, a fourth biopath drug candidate, is a modified product from Prexigerboricin sharing the same drug substance with enhanced nanoparticle properties. This trial is expected to be conducted at several leading cancer centers and is planned initially to evaluate the safety of Prexigerboricin in solid tumor patients. Patients diagnosed with recurrent ovarian and endometrial cancer often have poor outcomes, and it is our hope that Prexager-Burison may provide clinical benefit for such patients. Turning now to BP1002, our second therapeutic candidate, which targets BCL2. In April, we presented a poster highlighting preclinical BP1002 data at the 2021 American Association for Cancer Research annual meeting. BP1002 targets the protein BCL2, which is responsible for driving cell survival in up to 60% of all cancers. High expression of BCL2 has been correlated with poor prognosis for patients diagnosed with AML. The data presented in the AACR poster show that venetoclax-resistant cells are sensitive to the inhibitory effects of BP1002 combined with the cytamine, suggesting that this combination is a potential treatment for patients who have relapsed from frontline venetoclax-based therapies. Venetoclax has also shown activity against anti-apoptotic protein BCL2 and works by neutralizing the protein's BH3 domain. It is an approved treatment for chronic lymphocytic leukemia, or CLL, patients and untreated AML patients. However, with the exception of some patients treated with allogenetic hematopoietic cell transplantation, disease relapse invariably occurs, oftentimes due to BH3 domain mutation over time. BP102 also targets the BCL2 protein, however, BP1002 activity is based on blocking the BCL2 messenger RNA and not the BH3 domain. As a result, we believe that BP1002 could provide an alternative for venetoclax patients who have relapsed, including AML patients who previously received venetoclax treatments. Finally, let me briefly review the progress we've made with our third drug candidate, BP1003, which targets the STAT3 protein. This program has shown promising preclinical data, and we are very excited for the future of this program. We are studying BP1003 for the treatment of pancreatic cancer in a patient-derived tumor model. Previous models have shown the drug to successfully penetrate pancreatic tumors and enhance the efficacy of standard frontline treatments. We are particularly excited to launch our first in-human validation of this cutting-edge therapy in an especially challenging cancer indication that has limited treatment options. We are aiming to file an IND application with this very promising product candidate later this year. With that, I'll now turn the program over to Anthony Price for a brief review of our first quarter 2021 financials, along with balance sheet highlights. Anthony?
spk03: Thanks, Peter. The company reported a net loss of 2.4 million, or 43 cents per share, for the three months ended March 31st, 2021, compared to a net loss of 3.3 million, or 90 cents per share, for the three months ended March 31st, 2020. Research and development expense for the three months ended March 31st, 2021 decreased to 1.3 million compared to 2.0 million for the three months ended March 31st, 2020, primarily due to decreased preclinical expense related to timing of activities for BP1003, as well as decreased clinical trial expense due to timing of activities for our Phase 2 clinical trial of Prexygebersin in AML and our Phase 1 clinical trial of BP1002 in lymphoma. General and administrative expense for the three months ended March 31st, 2021 decreased to $1.2 million compared to $1.3 million for the three months ended March 31st, 2020. primarily due to decreased franchise tax expense. As of March 31st, 2021, the company had cash of $30.8 million compared to $13.8 million as of December 31st, 2020. Net cash used in operating activities for the three months ended March 31st, 2021 was $1.6 million compared to $2.5 million for the comparable period in 2020. Net cash provided by financing activities for the three months ended March 31st, 2021 was 18.6 million. With that, I'll now turn the call back over to Peter.
spk07: Thanks, Anthony. As I hope we've conveyed on the call this morning, we have made great progress in 2021 that leaves us well positioned to achieve value-creating milestones throughout the balance of the year. With our continued publication and presentation of data, we are building a body of scientific and clinical evidence in support of our programs while greatly enhancing the visibility of our platform among relevant audiences. It is my hope that with this expanded knowledge of the potential of our de-enabilized platform, we are building a groundswell of interest in our technology and the various ways it can be used. This should enhance clinical trial enrollment, business development efforts, and more. This is just the start, and I couldn't be more excited about the future of BioPath. With that operator, we're ready to open the call for questions.
spk02: Ladies and gentlemen, if you would like to ask a question at this time, please press star followed by the number one on your telephone keypad. Please stand by while we compile the Q&A roster. Again, that's star one. And our first question is from the line of Jonathan Ashoff with Roth Capital Partners.
spk04: Thank you, Erin. Congrats on the progress, Peter. Can you give us any kind of update on the clinical data release timing for PREX and 1002, you know, just particularly over the rest of this year and the first half of next year?
spk07: Yes. Good morning, Jonathan. We... As you know, I've been rebuilding my drug supply. We had a COVID plant occurrence that pushed off some of our batches, so we've been managing our enrollment to the supply we have. That will start ramping up starting early next week, and we have several batches planned for the end of the year. With that being said, I think that, you know, we're over half the ways and one towards 19, uh, invaluable in one of the cohorts. And, uh, there's a possibility we'll get that read out by the end of the year. Um, and certainly, uh, I think the first half of the following year would be the remaining two cohorts. But we had had pretty high response in treating. We were at one point treating 12 to 15 patients, but we needed to manage our supply. So that's the current view. We've been getting good results. You recall what we put on the six valuable safety run out patients. Safety profile was excellent and we had positive efficacy enhancement over all of the various front line treatments in the three cohorts. It's just, obviously it's a small data set. So that's the view I have right now.
spk05: Peter, what cohort is most enrolled with the treatment-naive one?
spk07: Currently is the third cohort with the venetoclax intolerant-resistant patients.
spk04: Okay. And then what's your biggest treatment landscape evolution concern in AML that could possibly force you to redesign the clinical path for PREX again?
spk07: You know, I'm not really that focused in that regard because whatever, you know, the way it's worked before, it's a combination treatment. So we all basically adapt if there's a change in the front line because that's typically the way people will want us to configure our treatment option. And I think... Venetoclax is settled in pretty much for these treatments, the main drug treatment, that with the satinib. And so I think we're well on the way. The other thing is every time we've done a treatment comparison or development, preclinically we always show an incremental efficacy benefit. So it's really just keeping... track with what's going on in the front line. And I view that to be a pretty stable thing right now. Certainly, in our third cohort, where you have the satinib and prexinuburacin, the satinib alone is the front line for those patients. And I think that's a relatively low bar for us. So I'm anxious for us to try to get to that. So, I mean, that's kind of my view.
spk04: Thank you, Peter.
spk02: Our final question comes from the line of Yi Chen with HC Wainwright.
spk08: Hi, Yi. Thank you. Hi. Hi, Peter. Thank you for taking my questions. Could you tell us the current enrollment status of the phase 1 lymphoma in the CIL trial? For the what? For the PP102 trial, the current enrollment status?
spk07: That trial has had one evaluable patient enrolled, and we're currently looking at other patients. We have good cancer centers. BP1002 is starting out slow, and the problem is, as you well know, When you do a dose escalating study, it's hard to get people started at the low end because the oncologist will say, well, it's a safety trial and you can't expect a lot of benefit at the low end. I mean, we're starting at 20 milligrams per meter squared. So you have to kind of struggle through those early phases. So we're looking to do that. But We had had very positive responses from our sites that want to participate. We have MD Anderson, Georgia Cancer Center, and Sarah Cannon. Those are all good sites. So we have three sites to do this dose escalating trial. So I think it will get more rapid once we get up into the higher doses.
spk08: Do you believe this one trial can still report data before the end of this year?
spk07: Yes. It'd be a cohort. And again, the focus on the first one, for example, three patients at 20 milligrams per square meter would be the first cohort. It'd be safety. I don't know how much efficacy you can report on that early dose. So it would go from 20, 40, 60, and 90 are our dose points. They may go 135, but I think those first four are the ones that would be the principal focus. So we certainly ought to be able to get one of those, that first cohort in.
spk08: Okay, got it. And for Prexin-Driversin-A, How quickly do you think the phase one trial in solid tumors can recruit patients in the current environment of the pandemic?
spk07: Well, there seems to be a lot of, you know, this is going to be a, you know, a treatment for solid tumors that, you know, is systemic to IV and, you know, uh, endometrial and, uh, advanced ovarian are, uh, one of them they can recruit in pancreatic. We've done testing in that. And, uh, so the interest has been very high and, uh, you know, we have again, MD Anderson in that, uh, I recall, uh, we have a couple others that, uh, uh, would be coming in. We, uh, have waited these extra four months, the FDA had asked us to do two more sets of testing, and one of them was the particulates. And particulates are hard for us because of our product being a little bit different. You have to do it on the drug product, which is reconstituted liposomes. And so you have to, for those, you have to go through mechanisms to break down all the liposomes and just get the bare particles. And some of the things you use... to do that and aggregate themselves and coalesce and make a little more challenging. But we, in fact, have now just got the word in the last week or two that we've got that test successfully done. And so the FDA in the December call we had with them just gave us the two things we needed to do. So I think we'll get our IND here fairly quickly now. as we pass this in. And then there's a real need for this ye. And we've had, as you know, we've had two AACR papers that have been well-received posters at their annual meeting. And so, you know, I think there's a lot of interest in getting a kind of treatment like this that can help manage that. Obviously, The first part, again, will be a safety assessment. Fortunately, since Plexiburicin is the same drug cell, since the formulation is different to get a better nanoparticle, smaller particles, but since that safety is out there with AML, we get the start of the higher dose. I think it's 60 milligrams per meter squared, so we may not have to go through the hurdle of people not wanting to enroll their patients if they don't think they can get any benefits. So I think we can maybe be better on that as well. But everything I know, this is a treatment that's really being looked for.
spk08: So we can expect this trial to be initiated in the third quarter, right?
spk07: Yes. And I think we'll get the IND pretty quickly because we satisfy them when they want. And once we get that IND, we'll be opened up, ready to go. So certainly we should be dosing our first patient in the third quarter for sure. Got it.
spk08: Thank you.
spk02: Thank you, ladies and gentlemen. That's the end of our Q&A session. I'd like to turn the call back over for any closing remarks.
spk07: Thank you again, everyone, for joining us and for your continued support of BioPath. Have a great day.
spk02: Ladies and gentlemen, this concludes today's conference call. We ask that you now disconnect your lines.
Disclaimer